STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

The item’s headline states that Eli Lilly’s Jaypirca has been approved as a first-line therapy for chronic lymphocytic leukemia (CLL), a regulatory milestone for the drug in a new treatment setting.

The accompanying excerpt is a STAT+ biotech newsletter/Readout teaser rather than a full report on the approval. It says the edition covers questions about cancer vaccines, stem cell clinics’ FDA potential, and more biotech news, along with stem cell “hijinx” and drug pricing woes.

The excerpt also includes a personal aside about the Readout’s inspiration and notes that the article is exclusive to STAT+ subscribers, with Meghana Keshavan identified as a biotech correspondent and Readout contributor. It does not provide trial data, approval specifics, or Jaypirca’s mechanism or prior indication.